| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.NEULET.2007.03.064 |
| P698 | PubMed publication ID | 17482358 |
| P50 | author | Lars Lannfelt | Q5935335 |
| Henrik Zetterberg | Q6252048 | ||
| Kaj Blennow | Q28321550 | ||
| Lennart Minthon | Q66724775 | ||
| Hans Basun | Q114441315 | ||
| P2093 | author name string | Niels Andreasen | |
| Peter Annas | |||
| Stig Strid | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 18-22 | |
| P577 | publication date | 2007-04-06 | |
| P1433 | published in | Neuroscience Letters | Q7002625 |
| P1476 | title | Longitudinal stability of CSF biomarkers in Alzheimer's disease. | |
| P478 | volume | 419 |
| Q41600997 | 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease |
| Q45310728 | Acetylcholinesterase protein level is preserved in the Alzheimer's brain |
| Q58700766 | Alterations of Coherent Theta and Gamma Network Oscillations as an Early Biomarker of Temporal Lobe Epilepsy and Alzheimer's Disease |
| Q100960870 | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias |
| Q36866566 | Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures |
| Q36099506 | Applied multimodal diagnostics in a case of presenile dementia. |
| Q34077530 | Applying New Research Criteria for Diagnosis of Early Alzheimer's Disease: Sex and Intelligence Matter |
| Q26858963 | Behavioral assays with mouse models of Alzheimer's disease: practical considerations and guidelines |
| Q37730012 | Biochemical markers in Alzheimer's disease clinical trials |
| Q37590663 | Biological fluid biomarkers in neurodegenerative parkinsonism |
| Q24622136 | Biological markers of amyloid beta-related mechanisms in Alzheimer's disease |
| Q37769104 | Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives |
| Q37118083 | Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? |
| Q53314302 | Biomarkers in Alzheimer's disease drug development |
| Q30651551 | Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease |
| Q27007086 | Biomarkers in dementia: clinical utility and new directions |
| Q37769463 | Biomarkers of Alzheimer's disease in body fluids |
| Q95579827 | Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease |
| Q59049398 | CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design |
| Q35835717 | CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. |
| Q37953330 | CSF biomarkers for amyloid and tau pathology in Alzheimer's disease |
| Q37253492 | CSF biomarkers in frontotemporal lobar degeneration with known pathology |
| Q35114771 | CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy |
| Q51959493 | Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? |
| Q36001286 | Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease |
| Q36071742 | Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort |
| Q33924646 | Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease |
| Q34098866 | Cerebrospinal fluid and plasma biomarkers in Alzheimer disease |
| Q43861285 | Cerebrospinal fluid beta-amyloid and dynabridging in Alzheimer's disease drug development |
| Q37381205 | Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type |
| Q33757828 | Cerebrospinal fluid biomarkers of Alzheimer's disease |
| Q48650878 | Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease |
| Q51891381 | Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. |
| Q53313228 | Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease. |
| Q41245550 | Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers |
| Q35284971 | Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease |
| Q37352061 | Commonalities in the genetics of Alzheimer's disease and Parkinson's disease |
| Q47827523 | Comparative analysis of cerebrospinal fluid metabolites in Alzheimer's disease and idiopathic normal pressure hydrocephalus in a Japanese cohort. |
| Q36985933 | Current state and future directions of neurochemical biomarkers for Alzheimer's disease |
| Q60310921 | Current state of Alzheimer's fluid biomarkers |
| Q57300558 | Diagnosis of neurodegenerative dementia: where do we stand, now? |
| Q36885492 | Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease |
| Q92138044 | Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers |
| Q48275229 | Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid |
| Q34215733 | Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system |
| Q35067938 | Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology |
| Q39997445 | Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment |
| Q36186513 | Fluid biomarkers in Alzheimer disease |
| Q36953503 | Fluid biomarkers in Alzheimer's disease - current concepts |
| Q53300571 | How can we recognize "disease modification" effects? |
| Q33769278 | Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics |
| Q49957645 | Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions |
| Q36923303 | Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors |
| Q37702259 | Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall |
| Q42371042 | Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery |
| Q38113683 | Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid |
| Q33419936 | Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data |
| Q92382299 | Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease |
| Q35006354 | Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease |
| Q33687554 | Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease |
| Q41719639 | Longitudinal change of biomarkers in cognitive decline |
| Q37254705 | Longitudinal study of CSF biomarkers in patients with Alzheimer's disease |
| Q36433310 | Miglustat treatment may reduce cerebrospinal fluid levels of the axonal degeneration marker tau in niemann-pick type C. |
| Q64948618 | Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. |
| Q33745951 | Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels |
| Q97522918 | Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study |
| Q34620335 | SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease |
| Q40064054 | Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial |
| Q49053063 | Serum levels of albumin-amyloid beta complexes are decreased in Alzheimer's disease |
| Q40065021 | Tau as a biomarker of neurodegenerative diseases. |
| Q58486506 | The Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions |
| Q36165011 | The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations |
| Q33841363 | The effect of apolipoprotein E (ApoE) genotype on biomarkers of amyloidogenesis, tau pathology and neurodegeneration in Alzheimer's disease |
| Q57167160 | The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease |
| Q50532647 | The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. |
| Q33624674 | Total and phosphorylated tau protein as biological markers of Alzheimer's disease |
| Q30845482 | Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease |
| Q53399432 | Use of CSF biomarkers in Alzheimer's disease clinical trials. |
| Q53446502 | Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. |
| Q51963599 | Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. |
| Q35158065 | Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease |
| Q33382837 | Voxel-based morphometry in Alzheimer's disease |
Search more.